News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Nick Colic

Advertisement

Articles by Nick Colic

Attacks on Pharmaceutical Improvement Patents

ByRobert L. Stoll,Nick Colic
August 21st 2019

Is Congress harming pharmaceutical research by limiting enforcement of improvement patents?

Advertisement

Latest Updated Articles

  • Attacks on Pharmaceutical Improvement Patents
    Attacks on Pharmaceutical Improvement Patents

    Published: August 21st 2019 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

Novartis Planning Layoffs for 550 Positions at Switzerland Facility

2

How Technology is Moving the Industry Away from Animal Testing: Q&A with Dr. Jo Varshney

3

How Do New GLP-1 Drugs Impact Businesses' Ability to Provide Them to Employees?

4

What Does the List of Approved Drugs Reveal About FDA's Priority Review Voucher Program?

5

Novo Nordisk’s Stock Reacts to Unsuccessful Phase III Trial Results

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us